November 1, 2019
Chugai Pharmaceutical said on October 30 that European and US regulators have accepted marketing applications for satralizumab (development code: SA237), an anti-IL-6 receptor humanized recycling antibody, for adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). The Medicines Agency...read more